Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Toth

Showing results (71-80 of 524) with videos related to

Pageof 53
Sort By:
Revue Medicale De La Suisse Romande|August 1, 1995
[The immature kidney]J P Guignard, V Matos, P Toth
Bollettino Dell'Istituto Sieroterapico Milanese|January 1, 1985
Relation of spastic and flaccid paralysis to retrograde transport of 125I-tetanus toxin and its 125I-Ibc fragment. Modulating effect of F (ab) antibodies directed to specific areas on the toxin moleculeA A Fedinec, P Toth, B Bizzini
Current Atherosclerosis Reports|January 12, 2013
Is the future of statins aligned with new novel lipid modulation therapies?Binh An P Phan, Peter P Toth
Toxicon : Official Journal of the International Society on Toxinology|January 1, 1988
Defining a region on tetanus toxin responsible for neuromuscular blockadeB Bizzini, P Toth, A A Fedinec
Dermatologic Therapy|December 17, 2008
Long-term efficacy of up to 15 months' efalizumab therapy in patients with moderate-to-severe chronic plaque psoriasisDarryl P Toth, Kim Papp, David Gratton
Angiology|September 16, 2017
C-reactive Protein Is Associated With Prevalence of the Metabolic Syndrome, Hypertension, and Diabetes Mellitus in US AdultsMohsen Mazidi, Peter P Toth, Maciej Banach
Expert Review of Cardiovascular Therapy|August 29, 2024
Closing the gap between guidelines and clinical practice for managing dyslipidemia: where are we now?Sohum Sheth, Maciej Banach, Peter P Toth
Archives of Medical Science : AMS|December 7, 2023
2023: The year in cardiovascular disease - the year of new and prospective lipid lowering therapies. Can we render dyslipidemia a rare disease by 2024?Maciej Banach, Stanisław Surma, Peter P Toth, et al.
Postgraduate Medicine|August 25, 2022
LDL-C target attainment in secondary prevention of ASCVD in the United States: barriers, consequences of nonachievement, and strategies to reach goalsJames Underberg, Peter P Toth, Fatima Rodriguez
International Journal of Women'S Health|February 18, 2014
Dyslipidemia in women: etiology and managementBinh An P Phan, Peter P Toth
Pageof 53

Showing results (71-80 of 524) with videos related to

Sort By:
Pageof 53
Revue Medicale De La Suisse Romande|August 1, 1995
[The immature kidney]J P Guignard, V Matos, P Toth
Bollettino Dell'Istituto Sieroterapico Milanese|January 1, 1985
Relation of spastic and flaccid paralysis to retrograde transport of 125I-tetanus toxin and its 125I-Ibc fragment. Modulating effect of F (ab) antibodies directed to specific areas on the toxin moleculeA A Fedinec, P Toth, B Bizzini
Current Atherosclerosis Reports|January 12, 2013
Is the future of statins aligned with new novel lipid modulation therapies?Binh An P Phan, Peter P Toth
Toxicon : Official Journal of the International Society on Toxinology|January 1, 1988
Defining a region on tetanus toxin responsible for neuromuscular blockadeB Bizzini, P Toth, A A Fedinec
Dermatologic Therapy|December 17, 2008
Long-term efficacy of up to 15 months' efalizumab therapy in patients with moderate-to-severe chronic plaque psoriasisDarryl P Toth, Kim Papp, David Gratton
Angiology|September 16, 2017
C-reactive Protein Is Associated With Prevalence of the Metabolic Syndrome, Hypertension, and Diabetes Mellitus in US AdultsMohsen Mazidi, Peter P Toth, Maciej Banach
Expert Review of Cardiovascular Therapy|August 29, 2024
Closing the gap between guidelines and clinical practice for managing dyslipidemia: where are we now?Sohum Sheth, Maciej Banach, Peter P Toth
Archives of Medical Science : AMS|December 7, 2023
2023: The year in cardiovascular disease - the year of new and prospective lipid lowering therapies. Can we render dyslipidemia a rare disease by 2024?Maciej Banach, Stanisław Surma, Peter P Toth, et al.
Postgraduate Medicine|August 25, 2022
LDL-C target attainment in secondary prevention of ASCVD in the United States: barriers, consequences of nonachievement, and strategies to reach goalsJames Underberg, Peter P Toth, Fatima Rodriguez
International Journal of Women'S Health|February 18, 2014
Dyslipidemia in women: etiology and managementBinh An P Phan, Peter P Toth
Pageof 53